Abstract
Nutrition has a major role in both cancer prevention and its therapy. In fact, dietary choices and physical activity are the two major modifiable determinants of cancer risk. The evidence suggests that one-third of the more than 500,000 cancer deaths in the United States can be attributed to these two factors each year (1). The recent observation of improved 5-yr survival rates for all cancers is encouraging because much of the research into early cancer detection and treatment appears to be invaluable (2). Unfortunately, the increase in 5-yr survival over time (1950 to 1990) had little relationship to changes in the mortality from cancer. There are several reasons that the 5-yr survival rates have increased. These include improvements in the treatment of established cancer, earlier identification of patients in their disease course, and early effective treatment regimens. Naturally, if more effective treatments of existing disease and more cancers are found early and treated, then mortality rates should decrease. The major explanation for improved 5-yr survival rates without improved mortality is simply changes in the diagnosis of cancer, including detection of subclinical cancers. However, epidemiological studies of populations whose diets are high in vegetables and fruits and low in animal fat, meat, and total calories have shown reduced risks for some of the most common types of cancer (3).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993; 270: 2207–2212.
Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000; 283: 2975–2978.
Byers T, Nestle M, McTiernan A, et al. Amercian Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2002; 52: 92–119.
Inagaki J, Rodriguez V, Bodey GP. Causes of death in cancer patients. Cancer 1974; 33: 568–573.
Delmore G. Assessment of nutritional status in cancer patients: Widely neglected? Support Care Cancer 1997; 5: 376–380.
Kern KA, Norton JA. Cancer cachexia. JPEN 1988; 12: 286–298.
Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol 1997; 24: 277–287.
Barber MD, Ross JA, Fearon KC. Disordered metabolic response with cancer and its management. World J Surg 2000; 24: 681–689.
Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population. Cancer 1989; 63: 330–334.
Knox LS, Crosby LO, Feurer ID, et al. Energy expenditure in malnourished cancer patients. Ann Surg 1983; 197: 152–162.
Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? JPEN 1987; 11: 8–13.
Ottery FD. Supportive nutrition to prevent cachexia and improve quality of life. Semin Oncol 1995; 22 (suppl 13): 98–111.
DeWys WD, Begg D, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 491–497.
Henriksson R, Rogo KO, Grankvist K. Interaction between cytostatics and nutrients. Med Oncol Tumor Pharmacother 1991; 8: 79–86.
Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology 1999; 13: 1003–1008.
Potischman N, Byers T, Houghton L, et al. Effects of breast cancer treatments on plasma nutrient levels: Implications for epidemiologic studies. Cancer Epidemiol Biomark Prevent 1992; 1: 555–559.
Jaakkola K, Lahteenmaki P, Laakso J, et al. Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer Res 1992; 12: 599–606.
Weijl NI, Hopman GD, Wipkink-Bakker A, et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol 1998; 9: 1331–1337.
Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000; 6: 1–10.
Goseki N, Yamazaki S, Shimojyu K, et al. Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: A randomized, prospective clinical trial. Jpn J Cancer Res 1995; 86: 484–489.
Pandit MK, Burke J, Gustafson AB, et al. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993; 118: 529–539.
Chan JC, Cockram CS, Critchley AJ. Drug-induced disorders of glucose metabolism: Mechanisms and management. Drug Safety 1996; 15: 135–157.
Perazella MA. Drug-induced hyperkalemia: Old culprits and new offenders. Am J Med 2000; 109: 307–314.
Mattox TW. Specialized nutrition management of patients receiving hematopoietic stem cell transplantation. Nutr Clin Pract 1999; 14: 5–15.
Izzedine H, Launay-Vacher V, Isnard-Bagnis C, et al. Drug-induced Fanconi’s syndrome. Am J Kidney Dis 2003; 41: 292–309.
Kintzel PE. Anticancer drug-induced kidney disorders: Incidence, prevention and management. Drug Safety 2001; 24: 19–38.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Canada, T.W. (2004). Drug-Nutrient Interactions in Patients With Cancer. In: Boullata, J.I., Armenti, V.T. (eds) Handbook of Drug-Nutrient Interactions. Nutrition and Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-781-9_21
Download citation
DOI: https://doi.org/10.1007/978-1-59259-781-9_21
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-5359-2
Online ISBN: 978-1-59259-781-9
eBook Packages: Springer Book Archive